Compare Carlyle Group Inc (CG) vs Canopy Growth Corp (CGC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Carlyle Group Inc vs Canopy Growth Corp — how do they compare? Carlyle Group Inc trades at $47.87 (market cap $17.23B), while Canopy Growth Corp trades at $1.03 (market cap $421.10M). The key difference: Carlyle Group Inc is far larger — about 40.9× Canopy Growth Corp's market cap, and Carlyle Group Inc pays a 2.9% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| CG | CGC | |
|---|---|---|
Market Cap | $17.23B | $421.10M |
Sector | Financials | Health |
52-Week High | $69.35 | $1.92 |
52-Week Low | $40.52 | $0.86 |
Dividend Yield | 2.9% | — |
Enterprise Value | — | $378.55M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Carlyle Group (CG) trades at $47.87, up 0.15% today, with a bullish technical signal and a consensus analyst price target of $59.14. Recent Q2 2026 earnings beat estimates, with EPS of $1.07 versus $0.91 expected, while revenue trends show volatility from $3.4B in 2024 to $3.2B in 2025. The stock is supported by strong institutional interest and dividend payments of $0.35 per share.
The outlook is positive with analyst buy ratings at 54%, but risks include declining net income margins and negative operating cash flows. Investment opportunity lies in valuation upside to the price target, though investors should monitor earnings consistency and macroeconomic impacts on asset management.
Canopy Growth (CGC) trades at $1.02, up 7.13% with a bullish technical signal. The company reported Q1 fiscal 2027 revenue growth of 13% to C$81.2 million and narrowed its EBITDA loss. While revenue trends show stabilization after declining from $520M in 2022 to $269M in 2025, the company continues to post significant net losses with a -222.36% margin. The balance sheet shows improvement with debt-to-asset ratio declining from 53.61% in 2023 to 33.13% in 2025.
CGC presents a high-risk opportunity with potential catalysts from cannabis rescheduling and European expansion. The stock trades below book value (P/B 0.86) but faces substantial execution risks amid persistent losses. Analyst sentiment is mixed with 33% buy ratings, reflecting optimism about restructuring progress versus concerns about profitability timeline.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →About Canopy Growth Corp
Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →
